https://www.biopharmawatch.com/news/ONC/beone-revolution-medicines-collaboration-onc BiopharmaWatch en 2026-08-10T17:03:00.000Z Samenvatting: BeOne Medicines en Revolution Medicines kondigen samenwerking aan voor klinische ontwikkeling en regionale commercialisering https://www.biopharmawatch.com/news/ONC/beone-revolution-collaboration-clinical-development BiopharmaWatch en 2026-08-10T17:02:00.000Z BeOne Medicines und Revolution Medicines kündigen Zusammenarbeit bei klinischer Entwicklung und regionaler Vermarktung an https://www.biopharmawatch.com/news/HELP/helus-pharma-participate-canaccord-growth-conference BiopharmaWatch en 2026-08-10T16:00:40.000Z Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston https://www.biopharmawatch.com/news/NTHI/neonc-phase-2a-data-readout-anticipation BiopharmaWatch en 2026-08-10T14:53:36.756Z NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears https://www.biopharmawatch.com/news/ONC/beone-revolution-medicines-collaboration-oncology BiopharmaWatch en 2026-08-10T14:01:00.000Z Riassunto: BeOne Medicines e Revolution Medicines annunciano una collaborazione per lo sviluppo clinico e la commercializzazione regionale https://www.biopharmawatch.com/news/CON/concentra-investor-conferences-2026 BiopharmaWatch en 2026-08-10T13:30:00.000Z Concentra to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/GOSS/kuehn-law-investigates-gossamer-bio BiopharmaWatch en 2026-08-10T13:24:00.000Z Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm https://www.biopharmawatch.com/news/BMRN/biomarin-participate-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-10T13:05:00.000Z BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-appoints-david-polinsky-board BiopharmaWatch en 2026-08-10T13:01:00.000Z Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-manufacturing-investment-houston BiopharmaWatch en 2026-08-10T13:01:00.000Z Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas https://www.biopharmawatch.com/news/NTHI/neonc-reports-q2-2026-results-and-phase-2a-data-readout BiopharmaWatch en 2026-08-10T13:00:31.000Z NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout https://www.biopharmawatch.com/news/NXTC/xcellon-biologics-acquires-nextcure-gmp-facility BiopharmaWatch en 2026-08-10T13:00:00.000Z Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics https://www.biopharmawatch.com/news/ADUS/addus-homecare-leadership-change-bickham-dixon BiopharmaWatch en 2026-08-10T13:00:00.000Z Addus HomeCare Announces Departure of Heather Dixon and Return of Brad Bickham as Chief Operating Officer on an Interim Basis https://www.biopharmawatch.com/news/IBRX/immunitybio-appoints-dr-jim-yong-kim-vice-chairman BiopharmaWatch en 2026-08-10T13:00:00.000Z ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman https://www.biopharmawatch.com/news/ARTL/artelo-phase-2-trial-art27-13-glaucoma BiopharmaWatch en 2026-08-10T12:47:00.000Z Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma https://www.biopharmawatch.com/news/KURA/kura-oncology-ziftomenib-publication-blood BiopharmaWatch en 2026-08-10T12:46:04.185Z Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-q2-2026-results BiopharmaWatch en 2026-08-10T12:45:25.758Z Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SILO/silo-pharma-european-patent-ptsd-therapy BiopharmaWatch en 2026-08-10T12:44:12.821Z Silo Pharma Granted European Patent Covering Novel PTSD Therapy https://www.biopharmawatch.com/news/AIM/aim-immunotech-reports-q2-2026-results-and-phase-3-plans BiopharmaWatch en 2026-08-10T12:36:00.000Z AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer https://www.biopharmawatch.com/news/NTHI/neonc-technologies-investor-call-phase-2a-results BiopharmaWatch en 2026-08-10T12:30:11.000Z NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-acquires-dura-driver-control-systems BiopharmaWatch en 2026-08-10T12:30:00.000Z Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue https://www.biopharmawatch.com/news/BDMD/baird-medical-alpmed-partnership-advancing-ire-technology BiopharmaWatch en 2026-08-10T12:30:00.000Z Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally https://www.biopharmawatch.com/news/WVE/wave-life-sciences-redomiciliation-delaware BiopharmaWatch en 2026-08-10T12:30:00.000Z Wave Life Sciences Announces Completion of Redomiciliation to Delaware https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T12:30:00.000Z Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13 https://www.biopharmawatch.com/news/TBPH/theravance-biopharma-q2-2026-results-update BiopharmaWatch en 2026-08-10T12:30:00.000Z Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/EHC/encompass-health-private-offering-senior-notes-2034 BiopharmaWatch en 2026-08-10T12:28:00.000Z Encompass Health announces launch of private offering of 5.875% senior notes due 2034 https://www.biopharmawatch.com/news/AMIX/autonomix-medical-dr-robert-schwartz-award BiopharmaWatch en 2026-08-10T12:20:00.000Z Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award https://www.biopharmawatch.com/news/DCGO/docgo-second-quarter-2026-results-announcement BiopharmaWatch en 2026-08-10T12:16:00.000Z DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026 https://www.biopharmawatch.com/news/ACXP/acurx-partnership-leiden-university-antibiotics BiopharmaWatch en 2026-08-10T12:01:00.000Z Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics https://www.biopharmawatch.com/news/QTRX/quanterix-appoints-jim-gute-cfo BiopharmaWatch en 2026-08-10T12:01:00.000Z Quanterix Names Jim Gute Chief Commercial Officer https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-launches-spy772-phase-2-trial BiopharmaWatch en 2026-08-10T12:00:24.000Z Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa https://www.biopharmawatch.com/news/HRTX/heron-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-10T12:00:23.000Z Heron Therapeutics Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RANI/rani-therapeutics-canaccord-genuity-conference BiopharmaWatch en 2026-08-10T12:00:12.000Z Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/TELO/telomir-zinc-suppresses-tumor-growth-tnbc-prostate-cancer BiopharmaWatch en 2026-08-10T12:00:00.000Z Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models https://www.biopharmawatch.com/news/NVO/novo-nordisk-aws-partnership-accelerate-drug-discovery BiopharmaWatch en 2026-08-10T12:00:00.000Z Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-phase-1-study-eli-002-7p BiopharmaWatch en 2026-08-10T12:00:00.000Z Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-h1-2026 BiopharmaWatch en 2026-08-10T12:00:00.000Z Alvotech to Report Financial Results for H1 2026 https://www.biopharmawatch.com/news/REPL/replimune-announces-pricing-150-million-offering BiopharmaWatch en 2026-08-10T12:00:00.000Z Replimune Announces Pricing of $150 Million Underwritten Offering https://www.biopharmawatch.com/news/QTRX/quanterix-financial-results-q2-2026 BiopharmaWatch en 2026-08-10T12:00:00.000Z Quanterix Releases Financial Results for the Second Quarter of 2026 https://www.biopharmawatch.com/news/RVTY/revvity-launches-superflex-prenatal-screening-system BiopharmaWatch en 2026-08-10T12:00:00.000Z Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing https://www.biopharmawatch.com/news/OMER/omeros-corporation-q2-2026-financial-results-announcement BiopharmaWatch en 2026-08-10T12:00:00.000Z Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/BSX/boston-scientific-wells-fargo-conference-2026 BiopharmaWatch en 2026-08-10T12:00:00.000Z Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results https://www.biopharmawatch.com/news/CRVO/cervomed-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-10T11:57:32.052Z CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-appoints-johnny-bennett-scientific-advisory-board BiopharmaWatch en 2026-08-10T11:30:00.000Z Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board https://www.biopharmawatch.com/news/GLAS/glass-house-brands-q2-2026-earnings-call BiopharmaWatch en 2026-08-10T11:30:00.000Z Glass House Brands to Host Second Quarter 2026 Earnings Call on August 13, 2026 https://www.biopharmawatch.com/news/SGRY/surgery-partners-q2-2026-results-guidance BiopharmaWatch en 2026-08-10T11:30:00.000Z Surgery Partners, Inc. Announces Second Quarter 2026 Results Reaffirms Full Year 2026 Guidance https://www.biopharmawatch.com/news/SLN/silence-therapeutics-phase-2-sanreco-trial-results BiopharmaWatch en 2026-08-10T11:30:00.000Z Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-q2-2026-results BiopharmaWatch en 2026-08-10T11:30:00.000Z Sonida Senior Living Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/KPTI/karyopharm-report-q2-2026-financial-results BiopharmaWatch en 2026-08-10T11:30:00.000Z Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/CBLL/ceribell-fda-clearance-eeg-ai-enhancements BiopharmaWatch en 2026-08-10T11:23:09.866Z Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review https://www.biopharmawatch.com/news/SLN/silence-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-10T11:15:00.000Z Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-10T11:14:36.051Z Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/MLTX/moonlake-phase-3-izar-1-trial-sonelokimab-results BiopharmaWatch en 2026-08-10T11:13:44.305Z MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TENX/tenax-phase-3-level-trial-results BiopharmaWatch en 2026-08-10T11:05:00.000Z Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint https://www.biopharmawatch.com/news/ACB/aurora-cannabis-2026-agm-results BiopharmaWatch en 2026-08-10T11:04:00.000Z Aurora, a Global Leader in Medical Cannabis, Announces Results of 2026 Annual General Meeting https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T11:03:00.000Z Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/APGE/abbvie-acquires-apogee-13511-per-share BiopharmaWatch en 2026-08-10T11:00:28.000Z Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates https://www.biopharmawatch.com/news/NXTC/avere-therapeutics-500-million-private-placement-avr-001 BiopharmaWatch en 2026-08-10T11:00:00.000Z Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-10T11:00:00.000Z Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BRKR/bruker-majority-investment-mimetas-drug-discovery BiopharmaWatch en 2026-08-10T11:00:00.000Z Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-anaphylm-study-results BiopharmaWatch en 2026-08-10T11:00:00.000Z Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film https://www.biopharmawatch.com/news/SION/sionna-therapeutics-cystic-fibrosis-update BiopharmaWatch en 2026-08-10T11:00:00.000Z Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update https://www.biopharmawatch.com/news/JBIO/jade-biosciences-q2-2026-financial-results-update BiopharmaWatch en 2026-08-10T11:00:00.000Z Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/GRFS/grifols-sparta-phase-3-trial-completion BiopharmaWatch en 2026-08-10T11:00:00.000Z Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-phase-3-level-trial-results BiopharmaWatch en 2026-08-10T11:00:00.000Z Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF https://www.biopharmawatch.com/news/LH/labcorp-fda-approval-companion-diagnostic-melanoma BiopharmaWatch en 2026-08-10T11:00:00.000Z Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma https://www.biopharmawatch.com/news/SI/shoulder-innovations-promotes-jon-osborne-cco BiopharmaWatch en 2026-08-10T11:00:00.000Z Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer https://www.biopharmawatch.com/news/ACH/accendra-health-tax-asset-preservation-plan BiopharmaWatch en 2026-08-10T10:50:00.000Z Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value https://www.biopharmawatch.com/news/ACH/accendra-health-q2-2026-financial-results BiopharmaWatch en 2026-08-10T10:45:00.000Z Accendra Health Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SCNI/scinai-appoints-eran-kuratz-supply-chain-leader BiopharmaWatch en 2026-08-10T10:34:00.000Z Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration https://www.biopharmawatch.com/news/VERU/veru-fiscal-2026-q3-results-phase-2b-trial-update BiopharmaWatch en 2026-08-10T10:30:00.000Z Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress https://www.biopharmawatch.com/news/ACH/accendra-health-ceo-retirement-announcement BiopharmaWatch en 2026-08-10T10:30:00.000Z Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search https://www.biopharmawatch.com/news/RVMD/revolution-medicines-beone-collaboration BiopharmaWatch en 2026-08-10T10:01:00.000Z Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration https://www.biopharmawatch.com/news/ONC/beone-revolution-collaboration-oncology-development BiopharmaWatch en 2026-08-10T10:00:00.000Z BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-lock-up-extension-2027 BiopharmaWatch en 2026-08-10T10:00:00.000Z Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-10 BiopharmaWatch en 2026-08-10T07:15:32.710Z Biotech Catalysts to Watch: Key Developments for August 2026 https://www.biopharmawatch.com/news/OCS/oculis-acquires-privosegtor-from-accure-therapeutics BiopharmaWatch en 2026-08-10T07:01:00.000Z Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company https://www.biopharmawatch.com/news/CDRE/seegene-global-screening-approach-gmcs BiopharmaWatch en 2026-08-10T07:00:00.000Z Seegene propose une approche globale de dépistage des infections de l'appareil génital dans le cadre de la Global Million Clinical Study (GMCS) https://www.biopharmawatch.com/news/IPHA/sobi-innate-partnership-lacutamab-t-cell-lymphoma BiopharmaWatch en 2026-08-10T06:32:00.000Z Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma https://www.biopharmawatch.com/news/IPHA/innate-pharma-lacutamab-phase-3-partnership-sobi BiopharmaWatch en 2026-08-10T06:30:00.000Z Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer https://www.biopharmawatch.com/news/IPHA/innate-pharma-partnership-sobi-lacutamab-ctcl BiopharmaWatch en 2026-08-10T06:00:00.000Z Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma https://www.biopharmawatch.com/news/CMMB/online-gambling-digital-payments-bonuses BiopharmaWatch en 2026-08-10T02:24:30.000Z Ovocný Zen 1Win – CZ Start Winning https://www.biopharmawatch.com/news/CMMB/online-casinos-technology-security-promotions BiopharmaWatch en 2026-08-10T02:24:28.000Z Bezplatné Online Kasino Bez Vkladu F1 . národní území Get Bonus Now https://www.biopharmawatch.com/news/CMMB/online-gambling-casino-platform-analysis BiopharmaWatch en 2026-08-09T22:40:01.000Z Slammer Și Bandit Cu O Singură Mână Înapoi Betmen Bet — RO Unlock Offer https://www.biopharmawatch.com/news/SLN/silence-therapeutics-sanreco-trial-results BiopharmaWatch en 2026-08-09T21:00:00.000Z Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera https://www.biopharmawatch.com/news/RDNT/radnet-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-09T20:00:00.000Z RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges https://www.biopharmawatch.com/news/IRTC/kuehn-law-investigates-irhythm-technologies BiopharmaWatch en 2026-08-08T19:35:00.000Z Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm